Referring to a Pharmaceutical formulation comprising an Antibody that has not undergone prior lyophilization as IgG1 in a histidine arginine buffer, pH 4.5 to 6.5, where the buffer is a buffer of histidine, arginine acetate acetate, pH 5.0 to 6.0 or tampon Histi succinate Dina - arginine succinate, pH 5.0 to 6.0 and the concentration of histidine or histidine acetate succinate is 5 mm to 100 mm. The formulation also comprises a Surfactant such as Polysorbate in a concentration of 0.0001% to 1.0%, methionine at a concentration of 5 mg \/ ml and EDTA. This formulation retards the degradation Product Antibody found in itREFERIDA A UNA FORMULACION FARMACEUTICA QUE COMPRENDE UN ANTICUERPO QUE NO HA SIDO SOMETIDO A LIOFILIZACION PREVIA TAL COMO IgG1 EN UN TAMPON DE HISTIDINA-ARGININA, pH 4,5 A 6,5, DONDE EL TAMPON ES UN TAMPON DE ACETATO DE HISTIDINA-ACETATO DE ARGININA, pH 5,0 A 6,0 O UN TAMPON DE SUCCINATO DE HISTIDINA-SUCCINATO DE ARGININA, pH 5,0 A 6,0 Y LA CONCENTRACION DEL ACETATO DE HISTIDINA O SUCCINATO DE HISTIDINA ES DE 5mM A 100 mM. LA FORMULACION TAMBIEN COMPRENDE UN SURFACTANTE TAL COMO POLISORBATO EN UNA CONCENTRACION DE 0,0001% A 1,0%, METIONINA EN UNA CONCENTRACION DE 5 mg/ml Y EDTA. DICHA FORMULACION RETARDA LA DEGRADACION DEL PRODUCTO ANTICUERPO QUE SE ENCUENTRA EN ELLA
